Scientific Poster Spotlight: Taste Assessment Study of Belumosudil to Inform an Integrated Pediatric Formulation Development Program
At the European Pediatric Formulation Initiative (EuPFI) conference in September 2021, Quotient Sciences  and Kadmon (a Sanofi company)  presented a poster describing a taste assessment study of belumosudil, a ROCK2 selective inhibitor developed by Kadmon (a Sanofi company) for the treatment of immune disorders, that was carried out by Quotient Sciences. An oral suspension was being investigated as a possible pediatric formulation for patients aged between 3 months and 12 years, and the aim of this study was to identify an optimal flavor and/or sweetener combination to improve palatability.
Twelve healthy, adult volunteers took part in a ‘sip-and-spit’ taste assessment of six different formulations, including one unflavored/unsweetened reference and five different flavor/sweetener combinations. The participants filled in a questionnaire to rate the overall acceptability and seven key taste characteristics of each formulation on a nine-point Likert scale.
The study identified multiple successful flavor and sweetener combinations that were able to improve palatability. It was determined that a formulation with either sweetener alone or in combination with a flavor would be suitable to enhance palatability and to take forward into a relative bioavailability assessment versus the reference adult tablet formulation.
1. Quotient Sciences: Ashley Willson, Mark Beville, Nand Singh, Nazim Kanji
2. Kadmon (a Sanofi company): Olivier Schueller, Galit Regev
To find out more about how Quotient Sciences can support your pediatric development program, click here.